• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Leadershippubdesk

Chelsea Clinton Is Holding a Fundraiser With the Embattled Theranos CEO

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
March 14, 2016, 5:55 PM ET
Democratic Presidential Candidate Hillary Clinton Holds New Hampshire Primary Night Gathering
HOOKSETT, NH - FEBRUARY 09: Democratic presidential candidate, former Secretary of State Hillary Clinton arrives for her primary night gathering with daughter Chelsea Clinton and husband, former President Bill Clinton at Southern New Hampshire University on February 9, 2016 in Hooksett, New Hampshire. Rival Sen. Bernie Sanders (D-VT) was projected the winner shortly after the polls closed. (Photo by Justin Sullivan/Getty Images)Photography by Justin Sullivan Getty Images

Embattled blood testing company Theranos, once a darling of the biotech startup community, has suffered its share of grief in the past year. But at least one high-profile operation isn’t ready to toss the firm by the wayside: Hillary Clinton’s 2016 presidential campaign.

Re/code reported on Monday that Theranos CEO Elizabeth Holmes is hosting a fundraiser for the Democratic frontrunner next week featuring the candidate’s daughter, Chelsea Clinton. The event is slated to take place at Theranos’ headquarters in Palo Alto, California.

Coins2Day reached out to both Theranos and the Clinton campaign to confirm the specifics of the fundraiser and will update this post if they respond.

The reported details are fairly typical, including tiered contributions ranging from $100 to $2,700 and opportunities to meet with the former First Daughter (Hillary Clinton is not expected to attend). But the idea of the fundraiser itself may raise some eyebrows given the regulatory roadblocks Theranos has recently encountered.

The company’s finger-prick blood testing technology, once hailed as potentially game-changing, has been challenged by media outlets such as the Wall Street Journal while the firm itself has been forced to fend off regulatory scrutiny from the FDA and Centers for Medicare & Medicaid Services. Theranos’ promises ensuring third-party validation for the tech have been slow to materialize.

The most concerning prospect for Theranos involves the pharmacy giant Walgreens (WBA) potentially cutting off its formidable relationship with the blood testing upstart.

Hillary Clinton has collected more than double the pharmaceutical industry donations of any other 2016 competitor during this election cycle.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.